While no financial figures are provided, ASCO acceptance is a material positive for clinical credibility and investor visibility. Monitor the May 21 abstract release and subsequent trial enrollment trends in IMPACT and ACAPELLA for signs of momentum. This could support future partnership or funding opportunities.
Price Chart
Executive Summary
Alpha Tau Medical announced that a pooled analysis of safety and efficacy data from 58 patients across three clinical studies of its Alpha DaRT therapy for advanced pancreatic cancer has been accepted for presentation at the 2026 ASCO Annual Meeting, a premier oncology conference. This represents a significant scientific validation of its clinical program and builds momentum for its ongoing IMPACT and ACAPELLA trials in the U.S. and France.
Key Facts
- Abstract titled 'Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer' accepted for presentation at the 2026 ASCO Annual Meeting.
- Pooled data includes 58 patients from three prospective clinical studies conducted in Canada and Israel.
- ASCO is the world's largest and most prestigious oncology conference; abstract acceptance is peer-reviewed and highly competitive.
- Alpha Tau highlighted this as a major milestone, validating the maturity and strength of its pancreatic cancer clinical evidence base.
- The company's flagship IMPACT trial in the U.S. and ACAPELLA trial in France are actively advancing.
Financial Impact
No direct financial impact disclosed; potential long-term upside from clinical validation and de-risking of development path.
Risk Factors
- Pooled data is preliminary and not yet peer-reviewed in full; final results may differ.
- Alpha Tau remains pre-revenue with significant funding needs; clinical progress does not guarantee commercial success.
- Forward-looking statements dominate the release; actual outcomes depend on trial execution and regulatory approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-047783 |
| Document: ea0287690-6k_alphatau.htm | 0001213900-26-047783 |
| Document: 0001213900-26-047783-index-headers.html | 0001213900-26-047783 |
| Document: 0001213900-26-047783-index.html | 0001213900-26-047783 |
| Document: 0001213900-26-047783.txt | 0001213900-26-047783 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 17w ago | 6-K | $1.02 $4.00 | ▲ +292.16% | ▲ +289.66% | — |
Jun 1, 2026 17w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +280.14% | — |
May 18, 2026 19w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +275.08% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 7, 2026 21w ago | 6-K | $1.02 $2.58 | ▲ +152.94% | ▲ +149.11% | — |
May 5, 2026 21w ago | 6-K | $1.02 $2.70 | ▲ +164.71% | ▲ +161.97% | — |
May 4, 2026 21w ago | 6-K | $1.02 $2.29 | ▲ +124.51% | ▲ +122.65% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access